- Home
- MBC vs DNTH Comparison
MBC vs DNTH Comparison
Compare MBC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- DNTH
- Stock Information
- Founded
- MBC 1954
- DNTH 2015
- Country
- MBC United States
- DNTH United States
- Employees
- MBC N/A
- DNTH N/A
- Industry
- MBC Agricultural Chemicals
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- DNTH Health Care
- Exchange
- MBC Nasdaq
- DNTH Nasdaq
- Market Cap
- MBC 1.6B
- DNTH 1.8B
- IPO Year
- MBC N/A
- DNTH N/A
- Fundamental
- Price
- MBC $11.04
- DNTH $43.59
- Analyst Decision
- MBC Strong Buy
- DNTH Strong Buy
- Analyst Count
- MBC 1
- DNTH 10
- Target Price
- MBC $15.00
- DNTH $68.00
- AVG Volume (30 Days)
- MBC 2.0M
- DNTH 702.5K
- Earning Date
- MBC 11-04-2025
- DNTH 11-05-2025
- Dividend Yield
- MBC N/A
- DNTH N/A
- EPS Growth
- MBC N/A
- DNTH N/A
- EPS
- MBC 0.63
- DNTH N/A
- Revenue
- MBC $2,757,800,000.00
- DNTH $3,078,000.00
- Revenue This Year
- MBC $0.13
- DNTH N/A
- Revenue Next Year
- MBC $3.29
- DNTH N/A
- P/E Ratio
- MBC $16.45
- DNTH N/A
- Revenue Growth
- MBC 1.77
- DNTH N/A
- 52 Week Low
- MBC $9.33
- DNTH $13.37
- 52 Week High
- MBC $18.43
- DNTH $44.21
- Technical
- Relative Strength Index (RSI)
- MBC 48.19
- DNTH 70.18
- Support Level
- MBC $9.33
- DNTH $39.82
- Resistance Level
- MBC $11.25
- DNTH $43.34
- Average True Range (ATR)
- MBC 0.46
- DNTH 2.64
- MACD
- MBC 0.06
- DNTH 0.63
- Stochastic Oscillator
- MBC 86.46
- DNTH 93.59
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.